(Q22251014)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

2

Frauke Zipp

Frauke

Zipp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

Axel Methner

Axel

Methner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

22 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

published in

Nature Reviews Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

72-73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

Effects of dimethyl fumarate on neuroprotection and immunomodulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

Potassium channel KIR4.1 as an immune target in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

T cells become licensed in the lung to enter the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

Insight into the mechanism of laquinimod action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.277

10.1038/NRNEUROL.2012.277

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

22 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338282%20AND%20SRC:MED&resulttype=core&format=json